Appointment of experts to support development of lead candidate VMB-100, an RNA-based therapy for Stress Urinary Incontinence Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, today announces the formation of an Advisory Board comprised of industry leaders in urology. These include Professor Roger Dmochowski of Vanderbilt University, Professor Margot Damaser of the […]
Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space Barcelona, Spain, 2 December 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer, today announces the appointment of Dr Michel Detheux as Independent Chair to […]
Building the team with experienced biotech experts and renowned leaders in the ADC field Underscores company’s commitment to progressing lead program on novel ADC target uPARAP Copenhagen, Denmark, December 1st, 2021 – Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announced today […]
Brings more than 15 years of CNS drug discovery and development experience Copenhagen, Denmark and Boston, US, 1st November 2021 – Muna Therapeutics (“Muna”), pioneering the development of novel, first-in-class small molecule therapeutics for neurodegenerative diseases, today announces the appointment of Dr. Niels Plath as Chief Scientific Officer. Read more…
Optimum is pleased to announce the appointment of Stella Lempidaki. With a strong scientific background, Stella brings 13 years of experience in life sciences in both academia and startups. Stella was part of the founding team at techspert.io, a Cambridge, UK based technology startup using the power of AI to facilitate knowledge exchange within the […]
